Illumina (NASDAQ:ILMN) Stock Rating Upgraded by Daiwa Securities Group

Illumina (NASDAQ:ILMN) was upgraded by investment analysts at Daiwa Securities Group from a “neutral” rating to an “outperform” rating in a report released on Thursday. The brokerage currently has a $155.00 price objective on the life sciences company’s stock. Daiwa Securities Group’s target price indicates a potential upside of 6.90% from the stock’s current price.

Several other analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Evercore reissued an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Stifel Nicolaus upped their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Barclays upped their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $134.88.

Illumina Stock Down 0.5%

Shares of NASDAQ ILMN opened at $145.00 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a 1 year low of $77.50 and a 1 year high of $155.53. The stock’s 50-day simple moving average is $128.03 and its 200-day simple moving average is $129.13. The firm has a market cap of $21.94 billion, a price-to-earnings ratio of 26.36, a PEG ratio of 2.41 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina will post 5.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently modified their holdings of the business. Elyxium Wealth LLC bought a new position in shares of Illumina in the fourth quarter worth $25,000. Board of the Pension Protection Fund acquired a new stake in Illumina during the fourth quarter worth about $26,000. Creative Capital Management Investments LLC increased its holdings in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the 4th quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the 4th quarter valued at approximately $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.